During this event, Cellectis leadership team and key opinion leaders presented the full Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel (UCART22) in r/r B-ALL
Cellectis R&D Day presentations
During its R&D Day, Cellectis provided clinical data from the Phase 1 BALLI-01 study of lasme-cel for transplant ineligible patients with r/r B-ALL).
Cellectis unveiled the design of the pivotal Phase 2, its planned registration path for lasme-cel's initial indication, as well as the commercial opportunity.
The event also included panel discussions with global hematology experts on the potential of lasme-cel to address the significant unmet need for heavily pretreated patients.